Astellas Pharma, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3942400007
JPY
2,145.00
-2 (-0.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
5,37,925.00
5,71,206.00
5,24,320.00
5,05,794.00
4,59,294.00
5,17,408.00
4,62,497.00
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
5,37,925.00
5,71,206.00
5,24,320.00
5,05,794.00
4,59,294.00
5,17,408.00
4,62,497.00
Raw Material Cost
1,29,431.00
1,49,129.00
1,38,252.00
1,27,596.00
1,09,419.00
1,33,493.00
1,16,928.00
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
3,035.00
2,446.00
2,693.00
5,898.00
3,907.00
4,227.00
5,048.00
Selling and Distribution Expenses
2,34,699.00
2,21,779.00
2,06,837.00
1,96,997.00
2,11,316.00
2,25,305.00
1,99,534.00
Other Expenses
9,290.80
7,314.90
6,889.80
6,580.00
7,232.20
7,486.50
8,046.10
Total Expenditure (Excl Depreciation)
4,60,073.00
4,46,503.00
4,16,680.00
3,96,291.00
3,96,964.00
4,37,890.00
4,01,971.00
Operating Profit (PBDIT) excl Other Income
77852
124703
107640
109503
62330
79518
60526
Other Income
-26,648.00
11,746.00
-768.00
-11,595.00
1,768.00
-1,91,580.00
-16,452.00
Operating Profit (PBDIT)
1,01,564.00
1,85,585.00
1,54,166.00
1,45,712.00
1,11,781.00
-60,898.00
94,091.00
Interest
3,035.00
2,446.00
2,693.00
5,898.00
3,907.00
4,227.00
5,048.00
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
4,08,494.00
4,22,077.00
3,86,068.00
3,78,198.00
3,49,875.00
3,83,915.00
3,45,569.00
Depreciation
50,360.00
49,136.00
47,294.00
47,804.00
47,683.00
51,164.00
50,017.00
Profit Before Tax
48,172.00
1,34,002.00
1,04,179.00
92,009.00
60,192.00
-1,16,290.00
39,028.00
Tax
4,408.00
33,634.00
24,977.00
21,994.00
-14,342.00
-20,699.00
2,639.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
43,617.00
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
43,617.00
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
43,617.00
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
18,29,044.00
17,63,122.00
16,12,427.00
14,81,792.00
15,13,255.00
14,93,809.00
15,29,842.00
Earnings per share (EPS)
24.2
55.85
44.06
38.11
41.73
-54.55
19.97
Diluted Earnings per share
24.2
55.85
44.06
38.11
41.73
-54.55
19.97
Operating Profit Margin (Excl OI)
14.47%
21.83%
20.53%
21.65%
13.57%
15.37%
13.09%
Gross Profit Margin
18.32%
32.06%
28.89%
27.64%
23.49%
-12.59%
19.25%
PAT Margin
8.11%
17.56%
15.11%
13.53%
16.31%
-18.87%
7.76%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is 17.12% vs 10.78% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is -41.76% vs 325.06% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 16.54% vs 27.38% in Mar 2025

stock-summary

Interest

YoY Growth in quarter ended Mar 2026 is -22.32% vs -6.67% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Astellas Pharma, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(JPY)
Change(%)
Net Sales
5,37,925.00
10,94,541.00
-5,56,616.00
-50.85%
Other Operating Income
0.00
0.00
0.00
Total Operating income
5,37,925.00
10,94,541.00
-5,56,616.00
-50.85%
Raw Material Cost
1,29,431.00
4,48,639.00
-3,19,208.00
-71.15%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
3,035.00
43,649.00
-40,614.00
-93.05%
Selling and Distribution Expenses
2,34,699.00
2,91,996.00
-57,297.00
-19.62%
Other Expenses
9,290.80
15,167.10
-5,876.30
-38.74%
Total Expenditure (Excl Depreciation)
4,60,073.00
9,35,955.00
-4,75,882.00
-50.84%
Operating Profit (PBDIT) excl Other Income
77,852.00
158,586.00
-80,734.00
-50.91%
Other Income
-26,648.00
-4,57,698.00
4,31,050.00
94.18%
Operating Profit (PBDIT)
1,01,564.00
-1,35,242.00
2,36,806.00
175.10%
Interest
3,035.00
43,649.00
-40,614.00
-93.05%
Exceptional Items
0.00
-1,11,902.00
1,11,902.00
100.00%
Gross Profit (PBDT)
4,08,494.00
6,45,902.00
-2,37,408.00
-36.76%
Depreciation
50,360.00
1,63,870.00
-1,13,510.00
-69.27%
Profit Before Tax
48,172.00
-4,54,662.00
5,02,834.00
110.60%
Tax
4,408.00
-86,615.00
91,023.00
105.09%
Provisions and contingencies
0
0
0.00
Profit After Tax
43,617.00
-3,68,470.00
4,12,087.00
111.84%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
43,617.00
-3,68,470.00
4,12,087.00
111.84%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
62.00
-62.00
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
43,617.00
-3,68,408.00
4,12,025.00
111.84%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
18,29,044.00
74,29,441.00
-56,00,397.00
-75.38%
Earnings per share (EPS)
24.20
-233.23
257.43
110.38%
Diluted Earnings per share
24.20
-233.23
257.43
110.38%
Operating Profit Margin (Excl OI)
14.47%
14.49%
0.00
-0.02%
Gross Profit Margin
18.32%
-26.57%
0.00
44.89%
PAT Margin
8.11%
-33.66%
0.00
41.77%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 53,792.50 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -5.83% vs 8.94% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 17.12% vs 10.78% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 4,361.70 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -56.52% vs 26.65% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -41.76% vs 325.06% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 12,821.20 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -26.25% vs 12.20% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 16.54% vs 27.38% in Mar 2025

Quarterly - Interest
Interest 303.50 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 24.08% vs -9.17% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -22.32% vs -6.67% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 14.47%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025